Monograph Details
|
|
Dermatological Disorders
> Skin infections (topicals)
|
|
BACTROBAN NASAL |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antibacterial. |
| Generic Name |
|
Mupirocin (as calcium) 2%; oint. |
| Also |
• BACTROBAN
• BACTROBAN CREAM
|
| Indications |
|
Eradication of nasal colonization of methicillin-resistant S. aureus (MRSA) in adult patients and healthcare workers in certain institutional settings during outbreaks of infections with MRSA (see literature). |
| Children |
|
Not recommended. |
| Adults |
|
Apply approximately 0.25g to inside of each nostril twice daily for 5 days. Spread ointment by repeatedly closing and releasing the nostrils for 1 minute after application. |
| Precautions |
|
Avoid eyes. Nasal use in high-risk patients: see literature regarding autoinfection. Discontinue if irritation or sensitization occurs. Prolonged use may result in superinfection. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Nasal: avoid other concomitant nasal products. |
| Adverse Reactions |
|
Topical: burning, stinging, pain, itching. Nasal: headache, rhinitis, respiratory disorder, pharyngitis, taste perversion, burning/stinging, cough, pruritus. |
| How Supplied |
Oint—22g
Cream—15g, 30g
Nasal (single-use) (1g)—10 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
